Novo Nordisk A/S vs PulteGroup, Inc. — how do they compare? Novo Nordisk A/S trades at $45.86 (market cap $207.31B), while PulteGroup, Inc. trades at $132.77 (market cap $24.77B). The key difference: Novo Nordisk A/S is far larger — about 8.4× PulteGroup, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| NVO | PHM | |
|---|---|---|
Market Cap | $207.31B | $24.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $142.56 |
52-Week Low | $35.29 | $110.11 |
Enterprise Value | $222.02B | $25.19B |
Dividend Yield | 3.76% | 0.8% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →